Hanx Biopharmaceuticals repurchases HKD 0.82 million in H shares, boosting treasury stock to 598,600 units

Bulletin Express05-13

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. reported that on 13 May 2026 it bought back 26,400 H shares on the Hong Kong Stock Exchange, paying a volume-weighted average of HKD 30.98 per share within a price range of HKD 30.00–32.50. The aggregate consideration totalled HKD 0.82 million.

Post-transaction, issued shares (excluding treasury shares) decreased by 0.019% to 135.62 million, while total issued shares remained unchanged at 136.22 million. Treasury shares rose to 598,600 units.

The buyback was executed under the mandate approved on 12 February 2026, which authorises the repurchase of up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 598,600 shares, equivalent to 0.44% of the issued share base on the mandate date. A moratorium on new share issues or treasury-share sales is in force until 12 June 2026.

The company confirmed that the repurchase complied with all applicable Hong Kong listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138449998?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138449998","market":"us","top_or_hot":-1,"title":"Hanx Biopharmaceuticals repurchases HKD 0.82 million in H shares, boosting treasury stock to 598,600 units","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. reported that on 13 May 2026 it bought back 26,400 H shares on the Hong Kong Stock Exchange, paying a volume-weighted average of HKD 30.98 per share within a price range of HKD 30.00–32.50. The aggregate consideration totalled HKD 0.82 million.</p>\n<p>Post-transaction, issued shares (excluding treasury shares) decreased by 0.019% to 135.62 million, while total issued shares remained unchanged at 136.22 million. Treasury shares rose to 598,600 units.</p>\n<p>The buyback was executed under the mandate approved on 12 February 2026, which authorises the repurchase of up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 598,600 shares, equivalent to 0.44% of the issued share base on the mandate date. A moratorium on new share issues or treasury-share sales is in force until 12 June 2026.</p>\n<p>The company confirmed that the repurchase complied with all applicable Hong Kong listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals repurchases HKD 0.82 million in H shares, boosting treasury stock to 598,600 units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals repurchases HKD 0.82 million in H shares, boosting treasury stock to 598,600 units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-13 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. reported that on 13 May 2026 it bought back 26,400 H shares on the Hong Kong Stock Exchange, paying a volume-weighted average of HKD 30.98 per share within a price range of HKD 30.00–32.50. The aggregate consideration totalled HKD 0.82 million.</p>\n<p>Post-transaction, issued shares (excluding treasury shares) decreased by 0.019% to 135.62 million, while total issued shares remained unchanged at 136.22 million. Treasury shares rose to 598,600 units.</p>\n<p>The buyback was executed under the mandate approved on 12 February 2026, which authorises the repurchase of up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 598,600 shares, equivalent to 0.44% of the issued share base on the mandate date. A moratorium on new share issues or treasury-share sales is in force until 12 June 2026.</p>\n<p>The company confirmed that the repurchase complied with all applicable Hong Kong listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1138449998","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138449998","pubTimestamp":1778674990,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. reported that on 13 May 2026 it bought back 26,400 H shares on the Hong Kong Stock Exchange, paying a volume-weighted average of HKD 30.98 per share within a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"Hanx Biopharmaceuticals回购82万港元H股库存增至59.86万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. reported that on 13 May 2026 it bought back 26,400 H shares on the Hong Kong Stock Exchange, paying a volume-weighted average of HKD 30.98 per share within a price range of HKD 30.00–32.50. The aggregate consideration totalled HKD 0.82 million.\nPost-transaction, issued shares (excluding treasury shares) decreased by 0.019% to 135.62 million, while total issued shares remained unchanged at 136.22 million. Treasury shares rose to 598,600 units.\nThe buyback was executed under the mandate approved on 12 February 2026, which authorises the repurchase of up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 598,600 shares, equivalent to 0.44% of the issued share base on the mandate date. A moratorium on new share issues or treasury-share sales is in force until 12 June 2026.\nThe company confirmed that the repurchase complied with all applicable Hong Kong listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138449998","isCrawlerRequest":true}